Shares of Rockwell Medical RMTI have rallied more than 36 percent Thursday afternoon following a boosted price target from one of the few analysts who currently cover the stock.
Traders and analysts are responding to news from Wednesday morning the company's SFP met both primary and secondary endpoints in a Phase 3 CRUISE-2 study. Shares of Rockwell rallied about 8 percent over the course of Wednesday's trading session.
Summer Street's Carol Werther lifted her price target on shares of Rockwell earlier from $20 to $25 while maintaining a Buy rating.
With Rockwell Medical shares last trading around $8.10, the Summer Street analyst's new price target represents potential upside of a whopping 200-plus percent from where the stock is currently trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in